Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/53552
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity

AutorTortajada, Agustín CSIC ORCID; Montes, Tamara CSIC; Martínez-Barricarte, Rubén CSIC; Morgan, B. Paul; Harris, Claire L.
Fecha de publicación15-sep-2009
EditorOxford University Press
CitaciónHuman Molecular Genetics 18(18):3452-61(2009)
ResumenMutations and polymorphisms in the gene encoding factor H (CFH) have been associated with atypical haemolytic uraemic syndrome, dense deposit disease and age-related macular degeneration. The disease-predisposing CFH variants show a differential association with pathology that has been very useful to unravel critical events in the pathogenesis of one or other disease. In contrast, the factor H (fH)-Ile62 polymorphism confers strong protection to all three diseases. Using ELISA-based methods and surface plasmon resonance analyses, we show here that the protective fH-Ile62 variant binds more efficiently to C3b than fH-Val62 and competes better with factor B in proconvertase formation. Functional analyses demonstrate an increased cofactor activity for fH-Ile62 in the factor I-mediated cleavage of fluid phase and surface-bound C3b; however, the two fH variants show no differences in decay accelerating activity. From these data, we conclude that the protective effect of the fH-Ile62 variant is due to its better capacity to bind C3b, inhibit proconvertase formation and catalyze inactivation of fluid-phase and surface-bound C3b. This demonstration of the functional consequences of the fH-Ile62 polymorphism provides relevant insights into the complement regulatory activities of fH that will be useful in disease prediction and future development of effective therapeutics for disorders caused by complement dysregulation
Descripción38 p.- 7 fig.
Versión del editorhttp://dx.doi.org/10.1093/hmg/ddp289
URIhttp://hdl.handle.net/10261/53552
DOI10.1093/hmg/ddp289
ISSN0964-6906
E-ISSN1460-2083
Aparece en las colecciones: (CIB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
2009_Tortajada et al_Hum Mol Genet.pdf652,36 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

66
checked on 14-abr-2024

SCOPUSTM   
Citations

112
checked on 19-abr-2024

WEB OF SCIENCETM
Citations

111
checked on 24-feb-2024

Page view(s)

370
checked on 24-abr-2024

Download(s)

256
checked on 24-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.